This invention relates to the treatment of androgen receptor-positive breast cancer in a subject, for example a female subject. Accordingly, this invention provides methods of: a) treating a subject suffering from breast cancer； b) treating a subject suffering from metastatic breast cancer； c) treating a subject suffering from refractory breast cancer； d) treating a subject suffering from AR-positive breast cancer； e) treating a subject suffering from AR-positive refractory breast cancer； f) treating a subject suffering from AR-positive metastatic breast cancer； g) treating a subject suffering from AR-positive and ER-positive breast cancer； h) treating a subject suffering from triple negative breast cancer； i) treating a subject suffering from advanced breast cancer； j) treating a subject suffering from breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and/or fulvestrant treatments； k) treating, preventing, suppressing or inhibiting metastasis in a subject suffering from breast cancer； l) prolonging survival of a subject with breast cancer, and/or m) prolonging the progression-free survival of a subject with breast cancer； comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound, comprising administering to the subject a therapeutically effective amount of a SARM compound of this invention.Cette invention concerne le traitement du cancer du sein positif aux récepteurs androgènes (AR+). L'invention concerne des méthodes permettant de : a) traiter une patiente atteinte d'un cancer du sein； b) traiter une patiente atteinte d'un cancer du sein métastatique； c) traiter une patiente atteinte d'un cancer du sein réfractaire； d) traiter une patiente atteinte d'un cancer du sein AR-positif； e) traiter une patiente atteinte d'un cancer du se
